Objective To evaluate the effect and pathological characters for patients with early esophageal carcinoma and intraepithelial neoplasia after endoscopic submucosal dissection (ESD). Methods 69 patients from January 2013 to January 2016 were treated with ESD at the early stage of esophageal carcinoma and intraepithelial neoplasia. The clinical features and the size of the lesions of all the patients were collected. Then analyzed postoperative complications and pathological characteristics. Results Among 69 cases, 16 were early esophageal cancer, 38 were high-grade esophageal neoplasia and 35 were low-grade esophageal neoplasia. The whole piece resection rate was 100.00 % (69/69), complete resection rate and curative resection rate was 95.65 % (66/69), respectively. The largest removal diameter is 7.0 cm. Biopsy accuracy was 69.57 % (48/69). Compared with biopsy, diagnostic accuracy with ESD specimens is higher. Conclusion The early esophageal carcinoma and intraepithelial neoplasia can be treated with ESD. ESD can resect lesions primarily, provide complete specimen for further pathological assessment and improve diagnostic accuracy.

Objective To study the effect and mechanism of down-regulating Silt2/Robo 1 signaling pathway on rabbit iliac artery after angioplasty restenosis. Methods The 30 male New Zealand white rabbits were divided randomly into 3 groups , namely the blank group , the control group , and the experimental group , 10 rabbits in each group. Hign-fat feeding , the rabbits were produced endothelial denudation of iliac artery stenosis model. Another 4 weeks of feeding , percutaneous balloon angioplasty was performed. Then R5 antibody was injected into the abdominal cavity. After 4 weeks of feeding ,angiography again. The results of angiography was analysied by image workstation. The concentrations of Slit2 and Robo1 was detected by ELISA. The iliac artery tissue examined by HE staining. Results The rabbit iliac artery after angioplasty restenosis animal model was set up successfully. Compared with the control group and the experimental group , the serum concentration of Slit2 and Robo1 were significantly higher (P < 0.01) than the blank group. But in the experimental group, the Slit2 and Robo1 serum concentrations were significantly lower than those in the control group (P < 0.05) after R5 antibody intervention. The area ratio stenosis and diameter stenosis rate of iliac artery were reduced that confirmed by angiography. Conclusion The expression of Slit2/Robo1 was significantly higher in the rabbit model of vascular restenosis. R5 antibody can effectively inhibit the expression of Slit2/Robo1. Down regulation of Slit2/Robo1 signaling pathway in the treatment of restenosis after angioplasty in rabbits.

Objective To investigate the effects of CD147/MMP-9 pathway on early left ventricular remodeling Methods 30 healthy eight-week male SHR were divided into 3 groups (n = 10 for each group). SHR group received tail vein injections of normal saline weekly; CD147 group received CD147 of 600 ng·kg-1 weekly; and CD147+DOX group received CD147 of 600 ng/kg weekly and intragastric administration of DOX ( doxycycline ) of 30 mg/kg daily . 10 healthy eight-week male Wistar-Kyoto rats (WKY group) were treated as SHR group. Echocardiography, myocardial sections microscopy examination (HE and VG stain), and Western blot (for assessing levels of MMP-9, TIMP-1, CD147, and collagen I and Ⅲin myocardial tissues) were performed on day 56. Left ventricular weight index (LVWI)was measured and calculated. Collagen volume fractions (CVF) were obtained by image analysis. Results As compared with WKY group , levels of CD147 , MMP-9 , and MMP-9/TIMP-1 were lower but TIMP-1 and collagenⅠand Ⅲ were significantly higher in SHR group. The abundance of CD147 and MMP-9 protein and the ratio of MMP-9/TIMP-1 were obviously increased in CD147 group than in SHR group (P < 0.05). Levels of CD147, MMP-9, and MMP-9/TIMP-1 did no differ between CD147+DOX group and CD147 group. LVWI and contents of collagenⅠand Ⅲ were obviously declined in CD147 group as compare with SHR group. Cardiomyocyte hypertrophy , partial myocardial fibre rupture , myocyte dissolution and fuzzy myocardial fibre boundaries , more abundant of collagen fibers, and higher CVF were found in SHR group. Cardiac fibrosis was significantly improved after CD147 intervention, but the action was suppressed as DOX was administrated simultaneously. Conclusions Early ventricular remodeling may be involved in the inhibition of CD147/MMP-9 pathway in SHR. Input of CD147 to upregulate the pathway can improve the remodeling.

OBJECTIVETo assess the feasibility and safety of using the modified active fixation pacing leads model to pace the right ventricular outflow tract septum.

METHODSA total of 136 patients undergoing artificial heart pacemaker implantation with active fixation pacing leads were randomized into two groups to receive conventional right ventricular outflow tract pacing (CRVOTP) or modified right ventricular outflow tract pacing (MRVOTP). The electrode lead wire core was modeled in a double-curved three-dimensional shape in CRVOTP group and in a J-shaped bend in MRVOTP group before fixation at the right ventricular outflow tract septum.

RESULTSRight ventricular outflow tract septum pacing was achieved successfully in all the patients. None of patients experienced serious complications. No significant differences were found between the two groups in the number of times of electrode fixation, pacing thresholds, impedance, R wave height or QRS wave width during the operation, but MRVOTP was associated with a reduced time of X -ray exposure and operation (P<0.05) due to the convenience in electrode modeling and in passing the leads through the tricuspid annulus and the direct access to the right ventricular outflow tract septum. Postoperative follow-up of the patients showed no incidence of active fixation pacing lead dislocation and comparable pacing thresholds of the ventricular electrodes, impedance, R wave height and QRS wave width between the two groups.

CONCLUTIONSUsing the modified active fixation pacing leads model to pace the right ventricular outflow tract septum can reduce the time of X -ray exposure and operation with a low probability of lead damage.

Objective To assess the feasibility and safety of using the modified active fixation pacing leads model to pace the right ventricular outflow tract septum. Methods A total of 136 patients undergoing artificial heart pacemaker implantation with active fixation pacing leads were randomized into two groups to receive conventional right ventricular outflow tract pacing (CRVOTP) or modified right ventricular outflow tract pacing (MRVOTP). The electrode lead wire core was modeled in a double-curved three-dimensional shape in CRVOTP group and in a J-shaped bend in MRVOTP group before fixation at the right ventricular outflow tract septum. Results Right ventricular outflow tract septum pacing was achieved successfully in all the patients. None of patients experienced serious complications. No significant differences were found between the two groups in the number of times of electrode fixation, pacing thresholds, impedance, R wave height or QRS wave width during the operation, but MRVOTP was associated with a reduced time of X-ray exposure and operation (P<0.05) due to the convenience in electrode modeling and in passing the leads through the tricuspid annulus and the direct access to the right ventricular outflow tract septum. Postoperative follow-up of the patients showed no incidence of active fixation pacing lead dislocation and comparable pacing thresholds of the ventricular electrodes, impedance, R wave height and QRS wave width between the two groups. Conclusion Using the modified active fixation pacing leads model to pace the right ventricular outflow tract septum can reduce the time of X-ray exposure and operation with a low probability of lead damage.

Objective To assess the feasibility and safety of using the modified active fixation pacing leads model to pace the right ventricular outflow tract septum. Methods A total of 136 patients undergoing artificial heart pacemaker implantation with active fixation pacing leads were randomized into two groups to receive conventional right ventricular outflow tract pacing (CRVOTP) or modified right ventricular outflow tract pacing (MRVOTP). The electrode lead wire core was modeled in a double-curved three-dimensional shape in CRVOTP group and in a J-shaped bend in MRVOTP group before fixation at the right ventricular outflow tract septum. Results Right ventricular outflow tract septum pacing was achieved successfully in all the patients. None of patients experienced serious complications. No significant differences were found between the two groups in the number of times of electrode fixation, pacing thresholds, impedance, R wave height or QRS wave width during the operation, but MRVOTP was associated with a reduced time of X-ray exposure and operation (P<0.05) due to the convenience in electrode modeling and in passing the leads through the tricuspid annulus and the direct access to the right ventricular outflow tract septum. Postoperative follow-up of the patients showed no incidence of active fixation pacing lead dislocation and comparable pacing thresholds of the ventricular electrodes, impedance, R wave height and QRS wave width between the two groups. Conclusion Using the modified active fixation pacing leads model to pace the right ventricular outflow tract septum can reduce the time of X-ray exposure and operation with a low probability of lead damage.

Objective:To study the mRNA expressions of bone morphogenetic protein 2 ( BMP2) in different types of gliomas and the relation between BMP2 mRNA expression and survival time, and to explore the role of BMP2 mRNA expression in prognosis evaluation in gliomas. Methods:The clinical data of 692 patients with gliomas in China Glioma Genome Atlas (CGGA) database were collected. Differences of BMP2 mRNA expression were compared among glioma patients with different histophiologic types, and patients with different gender and different ages, patients at primary or recurrent status, and those with different WHO grading, isocitrate dehydrogenase 1 (IDH1) mutation, 1P19q heterozygous deletion status, and molecular typing. The difference in survival time between patients with high and low BMP2 mRNA expression levels were compared in different categories of gliomas. Results:(1) The BMP2 mRNA expressions were different in different histopathological types of gliomas ( F=9.392, P=0.000); BMP2 expression in the oligodendroglioma subtype was the highest, followed by astrocytoma subtype and glioblastoma. The BMP2 relative mRNA expressions in male and female patients were 9.78±0.65 and 11.26±0.86, respectively, without statistical difference ( P>0.05). The BMP2 relative mRNA expressions in patients <43 years old and patients≥43 years old were 12.51±0.81 and 8.37±0.65, respectively, with significant difference ( P<0.05). The BMP2 relative mRNA expressions were 10.09±0.62 and 10.90±0.93, respectively, without significant difference ( P>0.05). The BMP2 relative mRNA expressions were 13.98±1.12, 12.88±0.88 and 5.18±0.64 in WHO grading II, III, and IV gliomas patients, respectively, with significant differences ( F=30.912, P=0.000). The BMP2 relative mRNA expressions in patients with IDH1 wild-type and IDH1 mutant were 2.73±0.16 and 17.47±0.85, respectively, with significant difference ( P<0.05). The BMP2 relative mRNA expressions in patients with 1P/19Q non-absence and 1P/19Q absence were 7.02±0.36 and 25.28±1.66, respectively, with significant difference ( P<0.05). In patients with lower graded glioma and glioblastoma, the BMP2 mRNA expressions in these patients with IDH mutation were significantly higher than those in patients with IDH wild-type ( P<0.05). (2) In patients with primary glioma and patients with recurrent glioma, the survival time of these patients with high BMP2 mRNA expression (≥4.68) was significantly longer than that of patients with low expression (<4.68, χ2=62.975, P=0.000; χ2=12.810, P=0.000). Conclusion:The BMP2 mRNA expression can be used as an index to predict the malignant degrees of gliomas; patients with high expression have longer survival time than those with low expression.

Objective:To analyze the expression of ATP binding cassette subfamily C member 8 (ABCC8) in different types of gliomas and its relation with overall survival of glioma patients.Methods:The ABCC8 mRNA data and clinical data (gender, age, histopathology, WHO grading, isocitrate dehydrogenase [ IDH] mutation status, 1p/19q deletion status and molecular types), and overall survival of 516 glioma patients from the Cancer Genome Atlas were collected, and the differences of ABCC8 mRNA expression in different types of glioma patients were compared. The differences of overall survival were compared between high (≥54.50) and low (<54.50) ABCC8 mRNA expression patients in different types of glioma patients. Results:(1) ABCC8 mRNA expression in primary glioma patients was significantly higher than that in recurrent glioma patients ( P<0.05). ABCC8 mRNA expression was the highest in oligodendroglioma patients, followed by astrocytoma patients; and glioblastoma patients had the lowest ABCC8 mRNA expression; the differences among glioma patients from subgroups of different histopathological types were statistically significant ( P<0.05). ABCC8 mRNA expression was the highest in patients with grade II glioma, followed by those with grade III ( P<0.05); and patients with grade IV had the lowest ABCC8 mRNA expression ( P<0.05); the differences among patients from subgroups of different WHO grading were statistically significant ( P<0.05). ABCC8 mRNA expression in glioma patients with IDH mutant was significantly higher than that in glioma patients with IDH wild-type ( P<0.05); and ABCC8 mRNA expression in patients with 1P/19Q deletion glioma was significantly higher than that in patients with 1P/19Q deletion ( P<0.05). ABCC8 mRNA expression in low-grade glioma patients and glioblastoma multiforme patients with IDH mutation was significantly higher than that in patients with IDH wild-type ( P<0.05). (2) In all patients with glioma, primary and recurrent glioma, oligodendroglioma, neuroastrocytoma, WHO low-grading (grade II) and WHO high-grading (grade III or IV) glioma, IDH mutation and IDH wild-type gliomas, and 1p/19q deletion and no deletion gliomas, patients with high ABCC8 mRNA expression had significantly higher overall survival time that those with low ABCC8 mRNA expression ( P<0.05). (3) Multivariate Cox analysis showed that ABCC8 mRNA expression was an independent factor for overall survival of patients with gliomas ( HR=0.747, P=0.025, 95%CI:0.579-0.963). Conclusion:The ABCC8 mRNA expression in glioma patients is related to the malignant degrees of gliomas, which can be used as an indicator to predict the prognoses of gliomas.

Objective:To investigate the mRNA expression of adenosine triphosphate binding cassette subfamily C member 8 (ABCC8) in gliomas and its application value as an index for predicting the prognosis of gliomas.Methods:The data of sex, age, histopathological type, WHO grade, isocitrate dehydrogenase (IDH) mutation, 1p/19q deletion, survival time and ABCC8 mRNA expression of 304 patients with gliomas (study group) in the Chinese glioma Genome Atlas (CGGA) database were collected. The prognostic factors of patients with gliomas were determined by univariate and multivariate Cox regression analysis. This result was verified by the data of 506 glioma patients in TCGA database and 271 glioma patients in REMBRANDT database.Results:The expression of ABCC8 mRNA in 304 cases of gliomas in the study group was 15.93±1.23. ABCC8 mRNA expression was correlated with age, histopathological type, WHO grade, IDH mutation status, 1p/19q deletion status and WHO molecular grade ( P<0.01). The median survival time of patients in ABCC8 mRNA high expression group was 85.60 months, which was significantly longer than 14.07 months in low expression group ( P<0.001). Univariate Cox regression analysis showed that age, histopathological type, WHO grade, IDH mutation status, 1p/19q deletion status, postoperative radiotherapy, postoperative chemotherapy and ABCC8 mRNA expression were related to the overall survival time of patients ( P<0.05). Multivariate Cox regression analysis showed that WHO grade ( HR=3.117, 95% CI: 1.970-4.930), 1p/19q deletion status ( HR=0.285, 95% CI: 0.155-0.526), postoperative chemotherapy ( HR=0.680, 95% CI: 0.488-0.948) and ABCC8 mRNA expression ( HR=0.690, 95% CI: 0.491-0.971) were independent factors for the overall survival of patients. In the TCGA dataset, the median survival time of patients with high ABCC8 mRNA expression group was 133.70 months, which was longer than 19.60 months of patients with low ABCC8 mRNA expression group ( P<0.001). In Rembrandt dataset, the median survival time of patients with high ABCC8 mRNA expression group was 37.93 months, which was longer than 15.83 months of patients with low expression group ( P<0.001). Conclusions:The expression level of ABCC8 mRNA in glioma is related to the degree of malignancy. The higher degree of malignancy, the lower the expression. The expression level of ABCC8 mRNA is an independent factor for the overall survival of patients with gliomas. The overall survival of patients with high ABCC8 mRNA expression is longer than that of patients with low ABCC8 mRNA expression.

Objective:To investigate the mRNA expression of adenosine triphosphate binding cassette subfamily C member 8 (ABCC8) in gliomas and its application value as an index for predicting the prognosis of gliomas.Methods:The data of sex, age, histopathological type, WHO grade, isocitrate dehydrogenase (IDH) mutation, 1p/19q deletion, survival time and ABCC8 mRNA expression of 304 patients with gliomas (study group) in the Chinese glioma Genome Atlas (CGGA) database were collected. The prognostic factors of patients with gliomas were determined by univariate and multivariate Cox regression analysis. This result was verified by the data of 506 glioma patients in TCGA database and 271 glioma patients in REMBRANDT database.Results:The expression of ABCC8 mRNA in 304 cases of gliomas in the study group was 15.93±1.23. ABCC8 mRNA expression was correlated with age, histopathological type, WHO grade, IDH mutation status, 1p/19q deletion status and WHO molecular grade ( P<0.01). The median survival time of patients in ABCC8 mRNA high expression group was 85.60 months, which was significantly longer than 14.07 months in low expression group ( P<0.001). Univariate Cox regression analysis showed that age, histopathological type, WHO grade, IDH mutation status, 1p/19q deletion status, postoperative radiotherapy, postoperative chemotherapy and ABCC8 mRNA expression were related to the overall survival time of patients ( P<0.05). Multivariate Cox regression analysis showed that WHO grade ( HR=3.117, 95% CI: 1.970-4.930), 1p/19q deletion status ( HR=0.285, 95% CI: 0.155-0.526), postoperative chemotherapy ( HR=0.680, 95% CI: 0.488-0.948) and ABCC8 mRNA expression ( HR=0.690, 95% CI: 0.491-0.971) were independent factors for the overall survival of patients. In the TCGA dataset, the median survival time of patients with high ABCC8 mRNA expression group was 133.70 months, which was longer than 19.60 months of patients with low ABCC8 mRNA expression group ( P<0.001). In Rembrandt dataset, the median survival time of patients with high ABCC8 mRNA expression group was 37.93 months, which was longer than 15.83 months of patients with low expression group ( P<0.001). Conclusions:The expression level of ABCC8 mRNA in glioma is related to the degree of malignancy. The higher degree of malignancy, the lower the expression. The expression level of ABCC8 mRNA is an independent factor for the overall survival of patients with gliomas. The overall survival of patients with high ABCC8 mRNA expression is longer than that of patients with low ABCC8 mRNA expression.